Literature DB >> 15825012

Cytomegalovirus hepatitis associated with use of anti-tumor necrosis factor-alpha antibody.

Mari Mizuta, Mindy G Schuster.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15825012     DOI: 10.1086/428672

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  6 in total

1.  Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment.

Authors:  Ismail Sari; Merih Birlik; Can Gonen; Servet Akar; Duygu Gurel; Fatos Onen; Nurullah Akkoc
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

Review 2.  Tumor necrosis factor blockade and the risk of viral infection.

Authors:  Seo Young Kim; Daniel H Solomon
Journal:  Nat Rev Rheumatol       Date:  2010-02-09       Impact factor: 20.543

3.  Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments.

Authors:  Jean-Luc Davignon; Jean-Frédéric Boyer; Bénédicte Jamard; Delphine Nigon; Arnaud Constantin; Alain Cantagrel
Journal:  Arthritis Res Ther       Date:  2010-07-15       Impact factor: 5.156

Review 4.  Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

Authors:  Fabrizio Cantini; Carlotta Nannini; Laura Niccoli
Journal:  Open Access Rheumatol       Date:  2009-12-04

Review 5.  Cytomegalovirus Hepatitis in Immunocompetent and Immunocompromised Hosts.

Authors:  Teresa Da Cunha; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2021-01-04

6.  Clinical use of anti-TNF therapy and increased risk of infections.

Authors:  Tauseef Ali; Sindhu Kaitha; Sultan Mahmood; Abdul Ftesi; Jordan Stone; Michael S Bronze
Journal:  Drug Healthc Patient Saf       Date:  2013-03-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.